Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, ...

April 1, 2025 – Advances in breast cancer screening and treatment have saved a lot of lives over the past few decades – for some groups more than others. Overall, the number of Americans ...

The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen receptor-negative (HER2-positive, ER-negative) breast cancer and has shown encouraging results in a ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more. See Healio’s ...

The FDA expanded the approval of trastuzumab deruxtecan (T-DXd, Enhertu) to include treatment of unresectable/metastatic hormone receptor (HR)-positive, HER2-low ...

Trastuzumab deruxtecan is approved for HR-positive, HER2-low/ultralow metastatic breast cancer post-endocrine therapy, based on DESTINY-Breast06 trial results. The trial showed a 36% reduction in ...

Although CDK4/6 inhibitors such as Ibrance are well-established treatments for HR-positive, HER2-negative breast cancer, a phase 3 trial sponsored by the cancer research organization Alliance ...

“Baywatch” star Nicole Eggert, 52, is prepping for radiation treatment in her battle against stage 2 cribriform carcinoma breast cancer, and she recently took ... The same approach is taken to hormone ...

Uncovering Surgical Dynamics and Trends in Early Breast Cancer Stage at Diagnosis: Key Insights From a Two-Decade Argentine Database Analysis A minimum of three or four clips were inserted into the ...

Uncovering Surgical Dynamics and Trends in Early Breast Cancer Stage at Diagnosis ... were recorded to assess for clip migration. After chemotherapy, the disease and clip mass were localized ...

HER2-positive (HER2+) breast cancer ... during and after cancer treatment. Areas of your skin could turn darker (hyperpigmentation), or red, or take on shades of black, blue, green, or yellow.